Home Ingredients Vinpocetine
Cognitive

Vinpocetine

Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Vinpocetine is a semi-synthetic derivative of vincamine — an alkaloid from periwinkle (Vinca minor). Developed in Hungary in the 1970s as prescription drug for cerebrovascular disorders (Cavinton®). Used in Eastern Europe and parts of Asia for stroke recovery, age-related cognitive decline, and tinnitus. Availability issues: FDA notified manufacturers in 2019 that vinpocetine doesn't meet dietary supplement criteria (not a vitamin, mineral, herb in dietary form, etc.); enforcement variable. Pregnancy absolutely contraindicated.

Studied Dose 5-10 mg three times daily (15-30 mg/day total); some research uses up to 60 mg/day
Active Compound Vinpocetine (apovincaminic acid ethyl ester)

Benefits

Cerebrovascular Insufficiency / Stroke Recovery (Eastern European Use)

Established prescription use in Hungary, Russia, parts of Eastern Europe and Asia for cerebrovascular disorders. Multiple trials show modest improvements in cognitive function, neurological recovery after stroke. Western/US clinical adoption limited.

Supported by Trial 1

Age-Related Cognitive Decline

Some trials in dementia and age-related cognitive decline show modest improvements in memory, attention, and cognitive function. Effect smaller than prescription Alzheimer's drugs.

Supported by Trial 1, Trial 2

Tinnitus

Some evidence for modest tinnitus improvement — particularly recent-onset tinnitus. Konopka 1997 and others suggest benefit; rigorous modern evidence limited.

Supported by Trial 2

Cerebral Blood Flow Enhancement

Direct effect — selective cerebral vasodilation. Increases blood flow to ischemic brain regions without affecting systemic blood pressure. Mechanism: PDE1 inhibition, sodium channel modulation, voltage-dependent calcium channel modulation.

Supported by Trial 2

Theoretical Neuroprotection

Animal studies show neuroprotective effects via multiple mechanisms — anti-inflammatory, antioxidant, sodium channel modulation. Clinical translation modest.

Supported by Trial 1, Trial 2

Mechanism of action

1

PDE1 Inhibition (Cerebral Selective)

Inhibits phosphodiesterase 1 (PDE1) — particularly in cerebral vasculature; increases cAMP and cGMP in cerebral vessels; selective cerebral vasodilation without significant systemic BP effects. Distinguishes vinpocetine from non-selective vasodilators.

2

Voltage-Dependent Sodium Channel Modulation

Inhibits voltage-dependent sodium channels — neuroprotective during ischemia (reduces excitotoxicity). Mechanism shared with some anticonvulsants.

3

Calcium Channel Modulation

Modulates voltage-dependent calcium channels — additional neuroprotective mechanism.

4

Anti-Platelet Effects

Modest antiplatelet activity — may contribute to cerebrovascular benefits but creates bleeding risk concerns.

Clinical trials

1
Vinpocetine for Cerebrovascular Disorders — Hungarian / Russian Trials

Multiple trials of vinpocetine (Cavinton®) in patients with cerebrovascular insufficiency, post-stroke recovery, and vascular cognitive impairment.

Cerebrovascular disease patients.

Modest improvements in cognitive function and neurological recovery. Established prescription status in Eastern European medicine; less recognized in Western medicine.

2
Vinpocetine for Tinnitus

Trials of vinpocetine for tinnitus, particularly recent-onset.

Tinnitus patients.

Modest improvements in tinnitus severity and audiometric measures. Limited rigorous modern evidence; mechanism via cerebral blood flow plausible.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Mild GI distress.
Headache.
Sleep disturbance.
Dizziness.
Hypotension (occasional).
Bleeding risk — antiplatelet effects; concerning for surgery, bleeding disorders.
Theoretical effects on heart rhythm in those with arrhythmia history.

Important Drug interactions

Anticoagulants (warfarin, DOACs, heparin) — additive bleeding risk; avoid without medical supervision.
Antiplatelet drugs (aspirin, clopidogrel, ticagrelor) — additive bleeding risk; consult.
Antihypertensives — additive BP effects (modest); monitor.
Anticonvulsants — sodium channel effects theoretically interactive.
Pre-surgery — discontinue 1-2 weeks before due to bleeding risk.
Pregnancy — vinpocetine has been associated with fetal harm; absolutely contraindicated.
Lactation — limited safety data; avoid.

More Cognitive Ingredients

Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Cognitive
Longvida® Optimized Curcumin (Verdure Sciences)
Longvida® is a patented curcumin extract developed by Verdure Sciences using SLCP™ (Solid…
Cognitive
CurQfen® (Curcumin-Fenugreek FenuMat — Akay Bioactives)
CurQfen® is a patented curcumin complex from Curcuma longa rhizomes formulated with FENUMA…
Cognitive
Ashwagandha
Ashwagandha (Withania somnifera) is an adaptogenic herb from Ayurvedic tradition, widely u…

Explore Other Ingredients

Cognitive
Citicoline
Citicoline (CDP-choline) is a naturally-occurring intermediate in phosphatidylcholine bios…
Cognitive
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid concentrated in neuronal cell membranes (10-20%…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…

Frequently asked questions about Vinpocetine

What is vinpocetine?

Vinpocetine is a compound derived from vincamine (from periwinkle), used for cognitive and circulatory support, particularly cerebral blood flow. It is sold as a supplement in the US but is a prescription medicine in some countries.

What is vinpocetine used for?

It is studied for supporting blood flow to the brain, memory, and cognitive function, especially related to circulation and age-related concerns. Its proposed mechanism involves widening blood vessels and supporting brain metabolism.

How much vinpocetine is used?

Studies have used about 15 to 30 mg per day, split into doses with meals. Follow product labeling. Note its regulatory status is under review in some places.

Who should avoid vinpocetine?

Pregnant women and those who could become pregnant should avoid it, as the US FDA has warned it may harm fetal development. It may also have mild blood-thinning effects, so check with your doctor if you take anticoagulants or have a medical condition.

What is the recommended dosage of Vinpocetine?

The clinically studied dose is 5-10 mg three times daily (15-30 mg/day total); some research uses up to 60 mg/day Always follow the product label and check with a healthcare provider for personal advice.

Is Vinpocetine safe, and does it have side effects?

For most healthy adults, Vinpocetine is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. Mild GI distress. It may also interact with some medications. Vinpocetine is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Vinpocetine interact with any medications?

Possible interactions include: Anticoagulants (warfarin, DOACs, heparin) — additive bleeding risk; avoid without medical supervision. Antiplatelet drugs (aspirin, clopidogrel, ticagrelor) — additive bleeding risk; consult. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Vinpocetine?

NutraSmarts rates the evidence for Vinpocetine as Moderate (3 out of 5). It is backed by 2 clinical trials and 6 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(6 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;2003(1):CD003119. doi: 10.1002/14651858.CD003119.PubMedUsed to support: Cochrane systematic review of vinpocetine for cognitive impairment and dementia, which found the human evidence inconclusive. Included honestly, framing the cognitive claims as unproven despite plausible mechanisms.
  2. Bönöczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002;15(1-2):85-91. doi: 10.1016/s0929-8266(02)00006-x.PubMedUsed to support: Clinical study (near-infrared spectroscopy) showing vinpocetine increased cerebral blood flow and oxygenation in stroke patients. Supports the cerebral-circulation mechanism.
  3. Szilágyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, Márián T, Molnár T, Szakáll S, Trón L, Bereczki D, Csiba L, Fekete I, Kerényi L, Galuska L, Varga J, Bönöczk P, Vas A, Gulyás B. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci. 2005;229-230:275-84. doi: 10.1016/j.jns.2004.11.053.PubMedUsed to support: Clinical PET study in which vinpocetine improved cerebral blood flow and glucose metabolism after stroke. Reinforces the brain-circulation mechanism.
  4. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007;60(7-8):301-10..PubMedUsed to support: Clinical investigation of vinpocetine's effects on cerebral blood flow and cognitive function. Supports the cognitive and circulation uses.
  5. Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs. 2017;31(9):759-776. doi: 10.1007/s40263-017-0459-3.PubMedUsed to support: Review of pharmacotherapy for vascular cognitive impairment that situates vinpocetine among options targeting cerebral perfusion. Context for the cognitive use.
  6. Vas A, Gulyás B. Eburnamine derivatives and the brain. Med Res Rev. 2005;25(6):737-57. doi: 10.1002/med.20043.PubMedUsed to support: Review of vinpocetine (an eburnamine derivative) and its brain pharmacology, including phosphodiesterase inhibition and neuroprotection. Supports the mechanism description.